PD-L1在急性髓系白血病中的表达及临床意义(1)
摘要：目的 探究程序性死亡分子1配体-1(PD-L1)在急性髓系白血病(AML)中的表达作用和临床意义。方法 选取2013年1月～2016年12月在我院进行治疗并确诊为AML的初治患者49例为观察组，选择同期在我院接受治疗的27例非恶性疾病如缺铁性贫血、巨幼细胞性贫血者作为对照组。对比两组患者血液中的PD-L1表达水平，分析患者性别、年龄、初诊白细胞计数、亚型的对血液中PD-L1的影响，确定PD-L1表达与临床疗效的相关性。结果 对照组患者治疗前的PD-L1表达与观察组比较，差异无统计学意义(P>0.05)。治疗后，观察组的PD-L1表达高于对照组，统计学意义显著(P<0.01)。单因素结果显示，PD-L1在AML初诊患者中的表达水平与患者的性别、年龄、初诊WBC数、分型无相关性(P>0.05);未缓解AML患者组PD-L1表达水平高于持续完全缓解组AML患者(P<0.01)。结论 PD-L1可能参与AML的免疫逃逸机制，并可能与病情进展及治疗效果相关。
关键词：PD-L1;急性髓系白血病;免疫
, 百拇医药
中图分类号：R733.71 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.06.025
文章编号：1006-1959(2019)06-0079-03
Abstract：Objective To investigate the expression and clinical significance of programmed death molecule 1 ligand-1 (PD-L1) in acute myeloid leukemia (AML). Methods From January 2013 to December 2016， 49 patients with initial diagnosis of AML were enrolled in our hospital. The observation group was selected from 27 non-malignant diseases such as iron deficiency anemia and giants treated in our hospital. A young cell anemia was used as a control group. The levels of PD-L1 in the blood of the two groups were compared. The effects of gender， age， white blood cell count， and subtype on PD-L1 in the blood were analyzed to determine the correlation between PD-L1 expression and clinical efficacy. Results There was no significant difference in the expression of PD-L1 between the control group and the observation group (P>0.05). After treatment， the expression of PD-L1 in the observation group was higher than that in the control group，the statistical significance was significant (P<0.01). Univariate results showed that the expression level of PD-L1 in newly diagnosed patients with AML was not correlated with gender， age， number of newly diagnosed WBC， and type (P>0.05). The expression of PD-L1 was higher in patients without AML. Patients with AML were continuously relieved (P<0.01). Conclusion PD-L1 may be involved in the immune escape mechanism of AML and may be related to the progression of the disease and the therapeutic effect.
, 百拇医药
Key words：PD-L1;Acute myeloid leukemia;Immunity
程序性死亡分子1配體-1(programmed death 1 ligand 1，PD-L1)，又名B7同源分子1(B7 homologue 1，B7-H1)或CD274，是B7/CD28共刺激分子家族的重要成员，这一免疫标记近年来因与肿瘤发生发展密切相关而成为研究热点。PD-L1与程序性死亡分子1(programmed death-1，PD-1)作为负性共刺激分子，两者结合后传递抑制性信号，降低淋巴细胞的免疫功能，削弱淋巴细胞的杀伤作用[1]。研究表明[2-6]，许多肿瘤细胞高表达PD-L1，如肺癌、肾癌、乳腺癌、肝癌、胃癌等，其可与肿瘤浸润淋巴细胞表面的PD-1结合，限制抗肿瘤免疫应答，参与肿瘤免疫逃逸。但之前的研究大多关注于实体肿瘤，少量研究表明在急性髓系白血病(acute myeloid leukemia，AML)等恶性血液系统疾病中PD-L1也存在高表达[2]。本研究检测急性髓系白血病患者的PD-L1的表达情况，探究其在急性髓系白血病中的临床意义。, 百拇医药(白雪 朱海波 邓琦)
关键词：PD-L1;急性髓系白血病;免疫
, 百拇医药
中图分类号：R733.71 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.06.025
文章编号：1006-1959(2019)06-0079-03
Abstract：Objective To investigate the expression and clinical significance of programmed death molecule 1 ligand-1 (PD-L1) in acute myeloid leukemia (AML). Methods From January 2013 to December 2016， 49 patients with initial diagnosis of AML were enrolled in our hospital. The observation group was selected from 27 non-malignant diseases such as iron deficiency anemia and giants treated in our hospital. A young cell anemia was used as a control group. The levels of PD-L1 in the blood of the two groups were compared. The effects of gender， age， white blood cell count， and subtype on PD-L1 in the blood were analyzed to determine the correlation between PD-L1 expression and clinical efficacy. Results There was no significant difference in the expression of PD-L1 between the control group and the observation group (P>0.05). After treatment， the expression of PD-L1 in the observation group was higher than that in the control group，the statistical significance was significant (P<0.01). Univariate results showed that the expression level of PD-L1 in newly diagnosed patients with AML was not correlated with gender， age， number of newly diagnosed WBC， and type (P>0.05). The expression of PD-L1 was higher in patients without AML. Patients with AML were continuously relieved (P<0.01). Conclusion PD-L1 may be involved in the immune escape mechanism of AML and may be related to the progression of the disease and the therapeutic effect.
, 百拇医药
Key words：PD-L1;Acute myeloid leukemia;Immunity
程序性死亡分子1配體-1(programmed death 1 ligand 1，PD-L1)，又名B7同源分子1(B7 homologue 1，B7-H1)或CD274，是B7/CD28共刺激分子家族的重要成员，这一免疫标记近年来因与肿瘤发生发展密切相关而成为研究热点。PD-L1与程序性死亡分子1(programmed death-1，PD-1)作为负性共刺激分子，两者结合后传递抑制性信号，降低淋巴细胞的免疫功能，削弱淋巴细胞的杀伤作用[1]。研究表明[2-6]，许多肿瘤细胞高表达PD-L1，如肺癌、肾癌、乳腺癌、肝癌、胃癌等，其可与肿瘤浸润淋巴细胞表面的PD-1结合，限制抗肿瘤免疫应答，参与肿瘤免疫逃逸。但之前的研究大多关注于实体肿瘤，少量研究表明在急性髓系白血病(acute myeloid leukemia，AML)等恶性血液系统疾病中PD-L1也存在高表达[2]。本研究检测急性髓系白血病患者的PD-L1的表达情况，探究其在急性髓系白血病中的临床意义。, 百拇医药(白雪 朱海波 邓琦)